Atea Pharmaceuticals Presents New Data Showcasing Potential

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also H

Related Keywords

Boston , Massachusetts , United States , Milan , Lombardia , Italy , Alina Jucov , Qi Huang , Jonae Barnes , Jean Pierre Sommadossi , Nasdaq , Corporate Communications , While The Company , Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Founder Of Atea Pharmaceuticals We , Include New Antiviral Efficacy Results , Lead In Cohort , Ongoing Phase , Also Highlight , High Prevalence , Resistance Associated Substitutions , European Association , Chief Executive Officer , European Time , Lead In Cohort Results From , Week Combination Regimen , Chronic Hepatitisc Virus , Favorable Antiviral Profile , High Resistance , Low Risk , Drug Interactions , Ruzasvir Based Upon In Vitro Metabolism , Transporter Interaction , Hepatitisc Virus , Private Securities Litigation Reform Act , Investor Relations ,